Grape King Bio Ltd (TPE:1707)
Taiwan
· Delayed Price · Currency is TWD 130.00
+0.50 (0.39%)
At close: Dec 5, 2025
Grape King Bio Revenue
Grape King Bio had revenue of 2.43B TWD in the quarter ending September 30, 2025, a decrease of -16.26%. This brings the company's revenue in the last twelve months to 10.40B, down -7.15% year-over-year. In the year 2024, Grape King Bio had annual revenue of 11.16B with 4.93% growth.
Revenue (ttm)
10.40B
Revenue Growth
-7.15%
P/S Ratio
1.85
Revenue / Employee
20.77M
Employees
501
Market Cap
19.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.16B | 524.54M | 4.93% |
| Dec 31, 2023 | 10.64B | 244.23M | 2.35% |
| Dec 31, 2022 | 10.39B | 592.99M | 6.05% |
| Dec 31, 2021 | 9.80B | 630.05M | 6.87% |
| Dec 31, 2020 | 9.17B | -70.88M | -0.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 34.99M |
| PharmaEssentia | 13.82B |
| Lotus Pharmaceutical | 18.66B |
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Oneness Biotech | 117.33M |
| Lumosa Therapeutics | 42.59M |
| Center Laboratories | 1.57B |
| Pegavision | 6.90B |